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Abstract
Background: HTLV-I is associated with adult T-cell leukemia, and both HTLV-I and -II are
associated with HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Several
published reports suggest that HTLV-I may lead to decreased survival, but HTLV-II has not
previously been associated with mortality.
Results: We examined deaths among 138 HTLV-I, 358 HTLV-II, and 759 uninfected controls
enrolled in a prospective cohort study of U.S. blood donors followed biannually since 1992.
Proportional hazards models yielded hazard ratios (HRs) for the association between mortality and
HTLV infection, controlling for sex, race/ethnicity, age, income, educational level, blood center,
smoking, injection drug use history, alcohol intake, hepatitis C status and autologous donation.
After a median follow-up of 8.6 years, there were 45 confirmed subject deaths. HTLV-I infection
did not convey a statistically significant excess risk of mortality (unadjusted HR 1.9, 95%CI 0.8–4.4;
adjusted HR 1.9, 95%CI 0.8–4.6). HTLV-II was associated with death in both the unadjusted model
(HR 2.8, 95%CI 1.5–5.5) and in the adjusted model (HR 2.3, 95%CI 1.1–4.9). No single cause of
death appeared responsible for the HTLV-II effect.
Conclusions: After adjusting for known and potential confounders, HTLV-II infection is associated
with increased mortality among healthy blood donors. If replicated in other cohorts, this finding
has implications for both HTLV pathogenesis and counseling of infected persons.
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Human T-lymphotropic viruses-I and -II (HTLV-I and -II)
are human retroviruses with worldwide distributions [1].
HTLV-I is endemic to southern Japan, to certain Melane-
sian peoples, and to Western and Equatorial Africa, the
Caribbean and Brazil. HTLV-II is endemic to indigenous
peoples throughout the Americas, as well as among injec-
tion drug users (IDU) in the U.S. and Europe. HTLV-I is
known to be associated with adult T-cell leukemia, uveitis,
arthropathy, and Sjögren Syndrome [1]. Both HTLV-I and
-II are associated with HTLV-associated myelopathy
(HAM, also known as tropical spastic paraparesis or TSP)
[2]. In addition, HTLV-II has been associated with an
increased incidence of pneumonia, bronchitis and urinary
tract infection [3-5].
Several investigators have reported an association
between HTLV-I and decreased survival rates among cer-
tain unique populations; namely HTLV-I-infected leprosy
patients in the Congo [6], and survivors of the atomic-
bomb dropped on Nagasaki [7]. In addition, there have
been a small number of reports of survival rates negatively
impacted by HTLV-I and viral co-infections; in particular,
hepatitis C (HCV)/HTLV-I dually infected persons in
Miyazaki, Japan [8]. The majority of studies of HTLV-II
infected populations have focused on HTLV-II/Human
Immuno-deficiency Virus (HIV) coinfection, particularly
among IDU, and have reported that HTLV-II has a mini-
mal effect on survival [9-12]. The impact of HTLV-I and -
II on mortality in otherwise healthy persons such as blood
donors has not been previously assessed.
Investigators with the HTLV Outcomes Study (HOST, for-
merly known as the Retrovirus Epidemiology Donor
Study, or REDS HTLV Cohort) have performed a prospec-
tive evaluation of health outcomes in a large cohort of
HTLV-I and HTLV-II infected subjects identified at the
time of blood donation. For this analysis, our primary aim
was to determine whether HTLV-I and -II are independ-
ently associated with an increase in mortality among
infected blood donors, as compared with matched unin-
fected blood donors.
Results
HOST enrolled 154 HTLV-I, 387 HTLV-II, and 799 unin-
fected donors (total enrollment; 1340). For this analysis,
subjects were excluded if their HTLV status could not be
confirmed or if they failed to complete an initial interview
and physical exam. The latter exclusion criterion insured
that persons with pre-existing, clinically apparent condi-
tions would not introduce bias. Mortality was ultimately
assessed in 1255 subjects (94% of the cohort), including
138 HTLV-I infected subjects (10% excluded), 358 HTLV-
II infected subjects (7% excluded), and 759 uninfected
controls (5% excluded). The characteristics of the subjects
at the baseline visits are given in Table 1. Age and gender
were similar among groups, but Black race was more com-
mon in the HTLV-I group. The HTLV-II group had lower
educational achievement and income, as well as higher
prevalence of cigarette smoking, alcohol intake, HCV
seropositivity and lifetime IDU, (although only 1 percent
admitted current IDU). Median follow-up time was 8.6
years, with a range of 1.1 to 11 years.
There were a total of 45 deaths in the cohort, including 8
(5.8%) HTLV-I, 19 (5.3%) HTLV-II and 18 (2.4%) HTLV
seronegative subjects. Crude survival was lower in both
the HTLV-I and HTLV-II groups than in the seronegative
subjects (Figure 1). HTLV-II infection conveyed a signifi-
cant independent risk of death (unadjusted HR 2.8,
95%CI 1.5–5.5; adjusted HR 2.3, 95%CI 1.1–4.9), but we
did not find a statistically significant association of HTLV-
I with mortality (unadjusted HR 1.9, 95%CI 0.8–4.4;
adjusted HR 1.9, 95%CI 0.8–4.6). No single cause of
death appeared responsible for the HTLV-II excess mortal-
ity, but numbers in all categories were small (Table 2).
Four (9%, 3 HTLV-negative, 1 HTLV-I) of 45 deaths in the
cohort were due to accidents or violence. Unadjusted and
adjusted hazard ratios for HTLV were calculated both by
censoring accidental and violent deaths, and by including
them among all causes of mortality. No significant differ-
ences in hazard ratios for any included variable resulted,
and these deaths are included among the total in the final
adjusted model (Table 3). Ten of the 45 deaths (22%)
were of subjects whose donations were autologous (those
who are donating for their own personal use, usually prior
to a planned surgery). Half of these were HTLV seronega-
tive subjects, two were HTLV-I infected, and three were
HTLV-II infected. Because of the possibility that autolo-
gous donors might be sicker than allogeneic donors, we
calculated the unadjusted hazard ratio (HR 0.9, 95%CI
0.4–1.9) for autologous donors and found that donation
type was not significantly associated with death. Inclusion
of a donation type variable did not have a significant
effect on the results of our adjusted model.
Because of the mortality risk inherent in IDU and the well-
established association between IDU and HTLV-II even in
blood donors [13-15], we assessed IDU status as a poten-
tial confounding variable. One percent of both the unin-
fected subjects and those with HTLV-I reported a lifetime
history of IDU, compared to 20% of those with HTLV-II
infection. Although IDU was a significant predictor of
mortality in the unadjusted model (OR = 3.5, 95% CI
1.5–8.0), the adjusted model indicated that a lifetime his-
tory of IDU was not significantly associated with mortality
(HR 2.0, 95%CI 0.7 – 6.3). Because of the high prevalence
of HCV co-infection in our HTLV-II group presumably
due to past IDU (see Table 1), we considered HCV infec-Page 2 of 9
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rate we found among those with HTLV-II. Among the 45
deaths, six (13%) were HCV positive; all of the subjects
with missing HCV data (n = 53; 4.2% of the entire cohort)
were alive at the time of our analysis. HCV infection was
not associated with mortality in our adjusted model (HR
= 1.1, 95% CI, 0.4 – 3.5).
We examined race as a potential confounder because of
the recognized association between Black race and
increased mortality and minor imbalances in race by
HTLV status. Black race was significantly associated with
death (adjusted HR 2.2, 95%CI 1.2–4.1). Alcohol intake
was the only other factor significantly associated with
mortality (p = 0.0069). Subjects who did not provide
information on their quantity of alcohol consumption
Table 1: Characteristics of HTLV mortality cohort study population at baseline showing number (percent) in each category, except as 
indicated.
Characteristics HTLV-I (n = 138) HTLV-II (n = 358) HTLV negative (n = 759)
Age in years (mean (range)) 46 (19–78) 42 (18–78) 44 (18–79)
Sex
Female 98 (71.0) 266 (74.3) 516 (68.0)
Male 40 (29.0) 92 (25.7) 243 (32.0)
Race/Ethnicity
Black 56 (40.6) 115 (32.1) 229 (30.2)
White 53 (38.4) 134 (37.4) 299 (39.4)
Other 29 (21.0) 109 (30.4) 231 (30.4)
Education
≤ high school 44 (31.9) 139 (38.8) 137 (18.1)
Some college 61 (44.2) 167 (46.6) 342 (45.1)
≥ college 33 (23.9) 52 (14.5) 280 (36.9)
Income
<$40 k 70 (50.7) 222 (62.0) 322 (42.4)
>$40 k 68 (49.3) 136 (38.0) 437 (57.6)
Donation type
Autologous 24 (17.4) 34 (9.5) 103 (13.6)
Allogeneic 114 (82.6) 324 (90.5) 656 (86.4)
IDU
Lifetime (past) 2 (1.5) 73 (20.4) 8 (1.1)
Never 132 (95.7) 260 (72.6) 730 (96.2)
Current 0 (0.0) 3 (0.8) 1 (0.1)
Missing 4 (2.9) 22 (6.1) 20 (2.6)
Smoking history (pack/year)
Non-smoker 67 (48.6) 122 (34.1) 403 (53.1)
1–15 29 (21.0) 120 (33.5) 190 (25.0)
>15 38 (27.5) 91 (25.4) 146 (19.2)
Missing 4 (2.9) 25 (7.0) 20 (2.6)
Alcohol intake (avg # drinks/week)
Mean (S.D.) 4.8 (12.2) 10.7 (30.4) 4.7 (12.9)
Non-drinker 17 (12.3) 19 (5.3) 67 (8.8)
1–14 109 (79.0) 268 (74.9) 620 (81.7)
>14 9 (6.5) 50 (14.0) 52 (6.9)
Missing 3 (2.2) 21 (5.9) 20 (2.6)
HCV Serology
Positive 6 (4.3) 68 (19.0) 8 (1.1)
Negative 120 (87.0) 253 (70.7) 747 (98.4)
Not available 12 (8.7) 37 (10.3) 4 (0.5)
Blood center region
Baltimore/Washington 28 (20.3) 49 (13.7) 118 (15.5)
Detroit 25 (18.1) 32 (8.9) 98 (12.9)
Southern California 43 (31.2) 193 (53.9) 325 (42.8)
San Francisco 28 (20.3) 62 (17.3) 145 (19.1)
Oklahoma 14 (10.1) 22 (6.1) 73 (9.6)
Note: Percentages may not sum to 100 due to rounding.Page 3 of 9
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ate alcohol consumption (HR = 3.5, 95% CI 1.4–8.9).
Our calculations of standardized mortality rates and ratios
demonstrated that the age-adjusted mortality rate of our
HTLV seronegative control donors was half that of the
general population (mortality rate = 354 per 100,000 per-
son-years, SMR = 0.6, 95% CI 0.3–0.9). Although both the
HTLV-I and -II infected former blood donors had almost
twice the mortality of the HTLV seronegative donors
enrolled and followed as an internal control group (rates
= 727 and 545 per 100,000 person years, respectively),
their standardized mortality ratios (SMR = 0.9, 95% CI
0.4–1.7 and SMR = 0.9, 95% CI 0.6–1.5, respectively)
were not significantly different from those of the general
U.S. population in the year 2000.
Discussion
We found that HTLV-II increased the risk of death in
infected blood donors relative to uninfected blood
donors, while HTLV-I infection had an adverse, but not
statistically significant, effect on mortality. No particular
cause of death was increased among the HTLV-II group,
although numbers were small in all cause of death catego-
ries. The association of HTLV-II with increased mortality
persisted after adjustment for multiple potential con-
founding factors, including race, socioeconomic status,
alcohol intake, cigarette smoking, HCV infection and
IDU. Although an etiologic basis for the mortality excess
cannot be identified from current information, the
pathogenic effects of chronic HTLV infection include tax
protein toxicity and HTLV-induced autoimmune
responses.
The HTLV-II association with increased mortality was
robust after consideration of bias or confounding by cov-
ariates that were not balanced between the groups in this
observational prospective cohort study. Black race and
alcohol intake were significantly associated with mortal-
ity, and there was a strong trend toward an effect by life-
time IDU, all plausible associations, which diminished
but did not nullify the HTLV-II effect in our multivariate
model. Nor did three other potential confounders,
namely educational attainment, HCV infection and autol-
ogous blood donation have an effect on mortality. The
groups were initially stratified by donation status because
autologous blood donors are a less healthy group than all-
ogeneic donors, with increased prevalence of several
infectious disease markers. Although HTLV-II subjects had
lower educational attainment compared to seronegatives,
this imbalance did not outweigh HTLV-II effects in this or
previous analyses of this cohort [4,5]. Finally, the preva-
lence of HCV infection was increased in the HTLV-II
group. Although some hospital-based studies suggest that
HCV frequently causes end-stage cirrhosis and hepatoma,
prospective studies of otherwise healthy HCV seroposi-
tives have not demonstrated increased overall mortality
[16,17].
There have been very few publications examining the
effect of HTLV-II on mortality [10-12], and all but one of
these [12] analyzed only HTLV-II/ HIV co-infection. None
found a significant effect of HTLV-II on either the course
of HIV disease or death. Goedert et al. [12] examined
HTLV-II among IDUs with and without HIV co-infection,
comparing mortality rates in these groups to that found in
uninfected IDUs and in the general population. They
found that IDU itself, in the absence of retroviral infec-
tion, was associated with a mortality rate over five times
that of the general population. While this rate was further
increased in the presence of HIV, these authors found no
Table 2: Number of deaths, by cause of death and HTLV status.
Cause of death HTLV-I (n = 138) HTLV-II (n = 358) HTLV negative (n = 759) All Subjects (n = 1255)
Accident/Trauma 1 0 3 4
Cancer 1 5 7 13
Cardiac 2 4 2 8
Cerebrovascular 2 2 1 5
Diabetes 0 1 0 1
Drug-related 1 1 0 2
Hepatic 0 1 0 1
Infection 0 1 3 4
Pulmonary 0 1 0 1
Other 0 0 1 1
Unknown 1 3 1 5
Total deaths 8 19 18 45
Deaths per group 5.8% 5.3% 2.4% 3.6%
Proportion of all deaths 17.8% 42.2% 40.0% 100%Page 4 of 9
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mortality.
What could explain the discrepancies between our esti-
mates of the effects of IDU and HTLV-II infection, and
those of studies such as Goedert et al? We believe that the
answer lies in a difference in study populations. Goedert
et al. studied current and chronic IDU, a population sub-
ject to high levels of competing mortality. Despite pre-
donation screening intended to exclude IDU, blood
donors who are deferred due to the discovery of a blood-
borne viral infection often reveal a past history of injec-
tion drug use in subsequent interviews [15,18]. We also
believe that only one percent of our subjects were still
actively injecting drugs because blood donors with IDU
experience tend to have remote and limited injecting his-
tories [15]. The dramatic mortality risk conveyed by IDU
in the Goedert et al. cohort is likely due to long-term and
ongoing IDU in the population studied. Although not, to
our knowledge, proven, it seems reasonable to surmise
that, once IDU behavior ceases, the risk that stems from it
recedes toward the individual's baseline risk, perhaps
explaining why we saw a small and non-significant effect
of IDU on mortality. Finally, competing mortality due to
the large effects of IDU and/or HIV may have obscured the
relatively small effect of HTLV-II in the Goedert et al.
cohort. Conversely, since we had less active IDU and no
HIV co-infection in our cohort, we were able to detect the
weaker association between HTLV-II and mortality.
HTLV-I was the first virus shown to cause cancer in
humans [19]. In addition, there is a well-established rela-
tionship between the virus and HAM/TSP, a chronic
degenerative neurologic disease, as well as a smaller body
of literature asserting the association between HTLV-I and
a number of autoimmune conditions [20,21]. Several
studies have also found an association between HTLV-I
and mortality [6-8]. Although the increased mortality in
our HTLV-I group was not statistically significant, these
other studies provide inferential support for our signifi-
cant association between HTLV-II and mortality. We rec-
ognize however that the existing literature on HTLV-I and
mortality is scant, and methodological problems and
unusual study populations make generalization particu-
larly difficult.
Proven links between HTLV-I, T-cell malignancy, and the
neurological disorder HAM/TSP involve putative pathoge-
netic mechanisms that may also be relevant to our mortal-
ity findings. One hypothetical mechanism of
pathogenicity is via direct effects of the HTLV-I tax viral
protein leading to either lymphocytic proliferation or
neurotoxicity [22,23]. Our own and other reports of high
proviral loads in most HTLV-I HAM/TSP patients support
this hypothesis [24-26]. A recent study has also linked
higher HTLV-I proviral load with mortality [27]. Another
hypothesis proposes that HTLV-I, and presumably HTLV-
II as well, causes an autoimmune phenomenon reflecting
an HTLV virus-induced host response against host anti-
gens in the central nervous system and other tissues [22].
Table 3: Factors associated with death in the HOST cohort: Hazard ratios (HRs) adjusted only for age, and adjusted for multiple 
covariates, are given for each variable.
Variable Unadjusted HR (95% CI) Adjusted HR (95% CI)1
HTLV status HTLV-negative 1.0 -------- 1.0 --------
HTLV-I 1.9 (0.8–4.4) 1.9 (0.8–4.6)
HTLV-II 2.8 (1.5–5.5) 2.3 (1.1–4.9)
Sex Female 1.0 -------- 1.0 --------
Male 1.4 (0.7–2.6) 1.6 (0.8–3.0)
Race/Ethnicity Non-Black 1.0 -------- 1.0 --------
Black 2.2 (1.2–4.0) 2.2 (1.2–4.1)
Donation type Allogeneic 1.0 -------- 1.0 --------
Autologous 0.9 (0.4–1.9) 0.6 (0.3–1.4)
HCV status HCV negative 1.0 -------- 1.0 --------
HCV positive 2.3 (1.0–5.6) 1.1 (0.4–3.5)
IDU history Never 1.0 -------- 1.0 --------
Ever 3.5 (1.5–8.0) 2.0 (0.7–6.3)
Alcohol use 1–14 drinks/week 1.0 -------- 1.0 --------
None 0.6 (0.2–1.9) 0.6 (0.2–2.0)
>14 drinks/week 0.5 (0.2–1.8) 0.4 (0.1–1.2)
Missing 4.3 (1.8–10.5) 3.5 (1.4–8.9)
Adjusted for HTLV status, age, gender, race, donation type, HCV status, IDU and drinking.Page 6 of 9
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HAM/TSP, as well as arthritis, uveitis and polymyositis, in
a minority of persons with HTLV-I or -II. However, as the
dead included no HAM/TSP patients and only one ATL
patient, and no other predominant cause of death
emerged, the relevance of HTLV tax protein toxicity or
virus-induced immune response to mortality remains
speculative.
A major strength of our study is the absence of subjects
with HIV and low numbers of those with active IDU, thus
eliminating competing conditions with large impacts on
mortality, which could have obscured the more subtle
effect of HTLV. We excluded subjects without baseline
questionnaire or exam and there was stratified enrollment
of our HTLV and seronegative subjects on age, sex, race,
blood center and donation type to improve comparability
of the groups. Our analysis controlled for other potential
confounders such as socioeconomic status and IDU.
Finally, we used a prospective study design, our follow-up
time was long and our ascertainment of deaths was active
and complete in contrast to studies which relied upon
death registries.
On the other hand, weaknesses of the study include the
unusually healthy nature of the uninfected blood donor
control population, which may have caused an overesti-
mation of the effect of HTLV on mortality. In designing
the study, we considered and rejected using population
controls because our blood donor sampling frame was the
same for both HTLV and seronegative donors. We still
believe that comparison to the general population, as
shown in our SMR calculations presented above, is not a
priori more valid than our use of the internal blood donor
control group. Finally, this was an observational and not
a randomized study, so unrecognized confounding either
by socioeconomic status, for which we attempted to con-
trol, or by other variables for which we could not control,
may have biased our estimate of the HTLV-II effect on
mortality.
Conclusion
We have demonstrated a significant, independent associ-
ation between HTLV-II and increased mortality among
healthy blood donors. This finding requires replication in
other prospective studies of HTLV-II, preferably without
HIV or IDU, and in a population other than blood
donors. A prospective cohort study among HTLV-II
endemic Amerindians would be the ideal setting. Never-
theless, the majority of HTLV infections in the United
States are diagnosed in the setting of blood donation. If
confirmed, the results of this study will enable us to better
inform HTLV infected blood donors of the long-term
implications of their infections. These findings may also
stimulate further investigation into the causes of death
among HTLV-infected persons, and into the pathogenic
mechanisms which may underlie increased mortality.
Methods
Subjects and study design
This was a prospective cohort study. Blood centers in five
United States regions (Baltimore/Washington, Detroit,
Oklahoma City, San Francisco, and Los Angeles) partici-
pated in HOST (see Appendix). We asked several non-
HOST blood centers to refer HTLV seropositive patients to
the study to increase the sample of infected donors. Study
personnel contacted all donors with confirmed HTLV
serology since the initiation of HTLV-I testing in 1988
through July 1992 and offered enrollment in a general
health study of HTLV-I and HTLV-II. We selected HTLV-
seronegative controls from among all those persons who
donated blood at the five HOST blood centers between
1988 and July 1992. The study design called for an HTLV
negative-to-positive matching ratio of 2:1 within each
stratum based on age, sex, race/ethnicity, blood center,
and type of blood donation (allogeneic, autologous, or
directed). All subjects were HIV-seronegative at baseline.
The human subjects committees of the American Red
Cross, the Oklahoma Blood Institute, and the University
of California, San Francisco approved the study protocol.
Subjects were enrolled in the study based upon HTLV-I or
-II seropositivity as measured by licensed enzyme immu-
noassay screening and supplemental testing at the partici-
pating blood centers. Additional confirmatory testing and
HTLV-I versus HTLV-II typing consisted of a combination
of serologic and polymerase chain reaction (PCR) assays
as previously reported by Busch et al [28]. Subjects were
followed biannually through the fifth study visit in Febru-
ary 2000 through July 2001 with assessments and exami-
nations. If a subject did not respond to routine contact
attempts, we searched credit bureau records, U.S. Postal
Service change of address files, and other internet
resources. Eventually, if tracing attempts by study staff
were unsuccessful, a professional tracing specialist was
assigned to the subject. Forty-one of 45 (91%) subject
deaths and cause of death were confirmed by death certif-
icate, the remainder were confirmed by the Social Security
Death Index and/or discussion with family members.
Causes of death were grouped into eleven categories (acci-
dental/trauma, cancer, cardiac, cerebrovascular, diabetes,
drug related, hepatic, infectious, pulmonary (non-infec-
tious), other and unknown). These categories did not
overlap.
Statistical analysis
Mortality rates were calculated separately for HTLV-I and
HTLV-II infected donors and HTLV negative donors. For
each group, the mortality rate was calculated as the
number of deaths per 100,000 person-years of observa-Page 7 of 9
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compared with the U.S. population as a whole, we com-
puted a standardized mortality ratio (SMR) for each HTLV
group using age-specific mortality rates for the U.S. popu-
lation [29]. For each HTLV group and seronegatives, the
age-specific mortality rates were applied to person years of
follow-up accrued within each age category to calculate
the expected age specific deaths, which were then
summed across age categories to obtain the expected
number of deaths in each group. Within each HTLV and
seronegative group, we then calculated the SMR as the
actual number of deaths divided by the expected number
of deaths. Confidence intervals (CI) for SMRs were com-
puted assuming a Poisson distribution.
The probability of survival in the HTLV-I, HTLV-II, and
HTLV negative groups was calculated using the Kaplan-
Meier method. For the analysis of predictors of mortality,
we used Cox proportional hazard models to obtain haz-
ard ratios (HR) for each HTLV group compared to the
HTLV negative group and for other cavariates, in both
unadjusted and adjusted analyses. Unadjusted hazard
ratios were derived from models including only the varia-
ble and age. The adjusted hazard ratios were determined
using a backward-selection procedure. Death was the
dependent variable, HTLV status was the primary inde-
pendent variable, and the following 11 variables were the
potential covariates: age, gender, race, education, income,
blood center, donation type, hepatitis C virus (HCV)
infection status, IDU, alcohol intake and smoking history.
Initially, we entered HTLV status and all 11 covariates into
the model. Variables were then sequentially removed,
starting with the least statistically significant. We forced
four covariates (gender, donation type, IDU, and HCV)
into the final model because of their reported association
with mortality, although they were not statistically signif-
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